American tegumentary leishmaniasis is an anthropozoonotic disease caused by protozoans of the genus Leishmania, which infect the vertebrate host after the host is bitten by infected phlebotomus insects of the genus Lutzomyia. The skin is the organ mostly affected (7) . The main line of defense against protozoal parasitic infection is the cellular immune response, which is responsible for the clinical spectrum of leishmaniasis, ranging from localized cutaneous leishmaniasis to its progressive form, diffuse cutaneous leishmaniasis (9, 30) .
The control of the infection is related to the generation of helper T cells by the host, which are able to deliver macrophage-activating cytokines, particularly gamma interferon and interleukin-2 (25) .
The humoral immune response occurs during the active phase of infection with the appearance of low titers of antibodies that disappear some months after the end of treatment, representing a temporary response (4) . This fact has made the assessment of antibody titers a useful tool for patient follow-up after therapy and for defining the period during which clinicians should observe patients in order to avoid mucosal complications (29) . In Colombia the most widely used technique for antibody assessment has been indirect immunofluorescence (IIF) with intact parasites (26) , although it has some limitations, including, in some cases, a low level of reactivity of serum, which prevents detection of antibodies at the time of diagnosis.
In the present study, we have examined patients' antibody responses at the time of diagnosis and posttreatment using the immunoblot technique with soluble Leishmania panamensis antigen. We had the double objective of identifying a particular band pattern present in patients affected by leishmaniasis (confirmed by the presence of parasites in a sample taken from the edge of the lesion) and describing any possible variation in this band pattern following therapy with meglumine antimoniate (Glucantime).
MATERIALS AND METHODS
Antigen. L. panamensis MHOM/CO/84/Med815 promastigotes were cultivated in tissue culture flasks with Schneider's Drosophila Medium (Gibco BRL, Gaithersburg, Md.) supplemented with 20% fetal bovine serum and antibiotics (penicillin, streptomycin, and gentamicin) (19) .
Parasites were taken at the late-logarithmic phase of growth, washed five times at 4°C with sterile phosphate-buffered saline (PBS), and centrifuged at 1,400 ϫ g for 15 min. The parasite pellet was resuspended in 1 ml of PBS, and the mixture was immediately frozen at Ϫ85°C. In order to make up only one batch of antigen for the Western blot analysis, all parasites were kept frozen at this temperature until there were sufficient parasites from which soluble antigen could be obtained.
To prepare the soluble antigen, the parasites were defrosted and resuspended in 2 ml of lysis buffer (20 (15, 17) . The mixture was left on ice for 30 min, with vortex agitation every 10 min. It was then centrifuged at 6,000 ϫ g for 20 min at 4°C. The supernatant was then removed and kept at Ϫ85°C until it was needed. A small sample was kept for protein determination by using the modified Lowry method (DC Protein Assay; BioRad, Hercules, Calif.). By this method the final antigen protein concentration was 3.42 mg/ml.
Human sera. A total of 140 serum specimens were studied: 47 serum specimens from patients with positive antibody titers for Chagas' disease (IIF or enzyme-linked immunosorbent assay [ELISA]), 86 serum specimens from patients with parasitologically confirmed cutaneous leishmaniasis, and 7 serum specimens from patients with no record of infection with trypanosomatids (normal sera). These last two groups were negative for antibodies to Trypanosoma cruzi. Sera were obtained by venipuncture from patients and controls. Blood was allowed to coagulate at room temperature and was then centrifuged at 1,400 ϫ g for 5 min. All sera were stored at Ϫ20°C until required.
Western blot analysis. SDS-polyacrylamide gel electrophoresis was done with a Mini-Protean II apparatus (Bio-Rad) as described previously (3). The antigen was boiled for 5 min in sample buffer, and it was immediately subject to electrophoresis in SDS-10% polyacrylamide gels. A wide-range molecular mass marker (Bio-Rad) was used. An antigen concentration of 227 g of protein was used in each preparative minigel. Gels were run at 100 V of constant voltage for 1.5 h in Tris-glycine-SDS buffer (pH 8.3).
Polypeptides from the SDS-polyacrylamide gels were electroblotted onto 0.45-m-pore-size nitrocellulose membranes (Bio-Rad). The blotting took place in transfer buffer (0.02 M Tris, 0.15 M glycine, 0.1% SDS, 20% methanol) at 250 mA of constant current for 1 h at 4°C. Following the blotting, the membranes were stained with 0.5% Ponceau Red for 5 min and were destained with distilled water. Blotted gels were stained with Coomassie blue in order to make sure that all polypeptides had been completely transferred. The dry membranes were kept refrigerated until use.
Immunoblotting. Detection of antibodies from patient sera bound to antigens of the Western blot was done with an avidin-biotin-alkaline phosphatase system, as indicated by the manufacturer (Vector Laboratories, Burlingame, Calif.).
Strips 4 mm wide were cut from previously blotted membranes and were blocked for 30 min in TTBS (100 mM Tris, 0.9% NaCl, 0.1% Tween 20) . Once blocked, these strips were incubated with diluted sera (1:3,200 in TTBS) for 30 min at room temperature with constant stirring. After incubation with the primary antibody the strips were washed four times for 15 min each time with TTBS. After the last wash biotinylated anti-human immunoglobulin G was added, and the mixture was incubated for 30 min under the same wash conditions described above. Preformed avidin-biotin-alkaline phosphatase complex was then added, and the mixture was incubated under the same conditions described above. The membranes were developed with the BCIP/NBT System (Vector Laboratories) for 5 min. The reaction was stopped with PBS-EDTA (20 mM) (14) .
Antibodies to T. cruzi. All sera from patients with cutaneous leishmaniasis and sera from patients with no record of infection with trypanosomatids were analyzed by a commercially available test for qualitative detection of antibodies to T. cruzi (Chagas antibody EIA; Abbott Laboratories, São Paulo, Brazil).
Statistical analysis. Analysis of corresponding polypeptides in the blotted membranes was done by using an exponential regression curve with the molecular mass markers of each membrane (Graphpad Prism Program), calculating the relative mobility (R f ) of each protein (13) , and looking for its corresponding molecular mass.
Multivariate and crossover analysis for statistical significance between the clinical characteristics and the immunoblotting results were done by using the Statgraphics Plus Program (version 6.0; Statistical Graphics Systems, Rockville, Md.).
RESULTS
Pretreatment sera. In general, the sera from patients with cutaneous leishmaniasis specifically recognized polypeptides ranging from 50 to more than 200 kDa, with the most frequent bands being of 120 kDa (76.7%), 123 and 129 kDa (69.7%), 138 (61.6%), 141 kDa (53.4%), and 78 kDa (44.1%). We did not find any bands common to 100% of the sera from patients with active disease (Fig. 1) . The immunoblots of control sera reacted with antigens of L. panamensis of more than 200, 81, 51, 39, 25, 23, and 21 kDa. It is interesting that the crossreactivity of normal sera was observed more frequently with proteins of low molecular mass. A similar band pattern was observed with sera from patients with Chagas' disease ( Fig. 1  and 2) .
Analysis of the specific band pattern for Leishmania infection revealed that the presence of this pattern is not associated with the titer of anti-Leishmania antibodies by IIF or with the number of parasites detected in the lesion at the time of diagnosis. An important observation was that the sera from patients with parasitologically positive lesions and with a negative IIF result presented a band pattern similar to the one observed with IIF-positive sera. Qualitatively, the band patterns of sera from patients with a negative IIF result were less intense than the patterns of sera from patients with a positive IIF result. All together, these observations suggest that immunoblot analysis is a more sensitive technique than IIF.
Likewise, we found no correlation between the immunoblot patterns and the clinical characteristics of the illness, such as the type or size of the lesion, reactivity to the Montenegro skin test, the presence of lymphadenitis, time of lesion development, or relapses.
Posttreatment sera. We studied 20 patients who were treated with meglumine antimoniate, and according to the Technical Administrative Standards of the Colombian Leishmaniasis Program, we did antibody tests every 2 months for 1 year. At the end of the follow-up period, only 45% of the patients were negative for anti-Leishmania antibodies by IIF. Among these 20 patients, 4 (20%) had relapses between 1 and 3 months after the treatment ended.
A 78-kDa protein was present in the pretreatment sera of 10 of the 20 patients followed during posttreatment (50%), while the overall frequency of occurrence of this protein in the leishmaniasis patients studied was 44.1%. This band disappeared with treatment. The serum of one of the patients with a relapse had this band during this period but not at the time of diagnosis (Fig. 3D) .
In general, excluding patients whose sera had the 78-kDa band, there were no changes between the specific band pattern when the pretreatment and the posttreatment sera were compared, especially for those patients whose last posttreatment serum sample was negative for anti-Leishmania antibodies and whose pretreatment serum had titers for anti-Leishmania antibody of between 1:16 and 1:128 (Fig. 3) . We only observed that the color intensity of the bands decreased for 50% of the patients, did not vary for 35% of the patients, and increased for 15% of the patients posttreatment.
Finally, the results suggest that the Western blot assay is more sensitive than IIF for the detection of anti-Leishmania antibodies, because some patients with a negative result by IIF were positive by Western blot analysis and had the same Western blot pattern as the patients with a positive result by IIF. However, the total absence of the parasite or any antigen derived from it cannot be ascertained by this method during the posttreatment period.
With the antigen used in this study, it was not possible to correlate some specific band with the presence of parasites in the lesions in 100% of the patients. Nevertheless, we propose that the band of 120 kDa could be helpful for the diagnosis of American cutaneous leishmaniasis, because we found a specific reactivity to this fraction in 76.7% of the patients. Also, an association of the 120-and 123-kDa bands was present in 61.6% of the serum specimens studied, and it could be helpful as well.
DISCUSSION
Parasitological methods have always been considered firstchoice procedures for the diagnosis of leishmaniasis due to their 100% specificities, although their sensitivities may vary depending on the experience of the diagnostic team. However, in some instances it is very difficult to demonstrate the presence of the parasite, such as in patients with mucocutaneous leishmaniasis or visceral leishmaniasis. In these patients, serodiagnosis becomes an important alternative for demonstrating the presence of the parasite (20) .
Several techniques have been developed for the serological diagnosis of leishmaniasis, from the complement fixation test described two decades after the discovery of this parasite to the production of recombinant antigens which react with human antibodies. The methods used so far have been indirect hemagglutination, the direct agglutination test, IIF, the gel diffusion test, counterimmunoelectrophoresis, immunoelectrophoresis, ELISA, dot ELISA, radioimmunoassay analysis, and Western blotting. The Western blot technique is among the most recently described methods, is highly sensitive and specific, and provides broader information about the parasite's antigenic profile (20) .
Most reports found in the literature have used a soluble promastigote extract as the antigen for the Western blot technique (6, 8, 10, 11, 16, 21-24, 27, 28) . Others have used subcellular fractions, specifically, parasite membranes (17, 18) . Comparing our results with the ones published by these groups, we found differences in the band pattern recognized by sera from patients with visceral leishmaniasis and cutaneous leishmaniasis using several Leishmania species as antigen. Dos Santos et al. (10) found reactivities with the 119-and 123-kDa bands when an extract of Leishmania chagasi was used as the antigen with sera from patients with visceral leishmaniasis. The reactivity of sera with the 119-kDa fraction was 66.6%, a value similar to that found in our study (76.7%). They were not able to find a band common to 100% of patients with visceral leishmaniasis. Also, it is remarkable in this study that the 119-and 123-kDa bands were not recognized by sera from patients with cutaneous leishmaniasis. Besides, Rolland-Burger et al. (27) found reactivity to a 119-kDa band in sera from patients with visceral leishmaniasis using Leishmania infantum as the antigen.
By Western blotting of soluble antigens of L. panamensis, several bands were recognized by sera from patients with confirmed infection, although none of the bands were present in all serum specimens. Similar observations have been reported by other investigators who used different species of Leishmania (10, 22, 27, 28) . However, there was little variation in the pattern recognized by each of the serum specimens since most of them showed the high-molecular-mass band pattern (Fig. 1) . Likewise, sera from patients with Chagas' disease recognized numerous Leishmania antigen bands, but only five of the bands (one of more than 200 kDa and bands of 39, 25, 23, and 21 kDa) were recognized by all three types of sera (serum specimens from patients with cutaneous leishmaniasis, those from patients with no record of infection with trypanosomatids, and those from patients with antibody titers positive for Chagas' disease). The recognition of numerous nonspecific Leishmania antigens by normal sera has been reported by other investigators (10, 17, 28) .
Despite the large number of positive serum specimens examined, this study was not able to demonstrate any association between the pattern recognized by Leishmania-positive sera and the anti-Leishmania antibody titer (IIF), the quantity of parasites detected in the wound at the time of diagnosis, or the clinical characteristics. Jaffe et al. (17) , Mary et al. (23) , and Rolland et al. (28) also reported no correlation between the antibody titer by radioimmunoassay, ELISA, or IIF with the intensity of the reaction or the number of bands recognized by Western blotting, although the same species was used in both the conventional serological test and Western blotting (Leishmania major and L. infantum). It is interesting that for patients who are negative for antibodies by any of these methods at the time of diagnosis, Western blotting could be a useful diagnostic tool, given its high degree of sensitivity. The same observation The only difference between the pre-and posttreatment sera was the disappearance of the 78-kDa protein and a decrease in the intensity of the signal. A similar lack of change was described by Evans et al. (11) for visceral leishmaniasis patients who were infected with L. chagasi and who were evaluated and followed for 1 year after therapy, when their fever had disappeared and their splenomegaly had decreased. Mary et al. (23) studied visceral leishmaniasis patients infected with L. infantum and postulated that anti-Leishmania antibodies remain in the blood of "cured" patients for years. Beverley et al. (5) proposed that on a molecular biology level, L. chagasi and L. infantum may effectively be the same species. If antibodies remain in the patient for years and the patient's serum has a Western blot pattern similar to the one at the time of diagnosis, then serious doubts arise as to whether a patient is ever completely cured (i.e., the patient has no remaining parasites) or whether treatment has induced a chronic subpatent infection, leaving the patient susceptible to relapse later on; for example, immunosuppression can lead to the reemergence of active infection, as in the case of visceral leishmaniasis in patients with AIDS (1, 2, 12) . Such a sensitive test as Western blotting may be able to identify immunosuppressed patients who could be at risk of a relapse of leishmaniasis.
Only one article in the literature describes a study in which L. panamensis antigens were used to study sera from patients with cutaneous leishmaniasis (8) . A discrepancy between the published results and ours was found. That study found that 100% of patients with Chagas' disease recognized one 20-to 30-kDa band from the Leishmania antigen (in the range of our cross-reacting bands) and a 38-kDa band which may correspond to the 39-kDa band that we detected. The article's authors postulated that these bands are specific for Chagas' disease. To evaluate the specificity of those bands for Chagas' disease we carried out an ELISA for Chagas' disease (Abbott Laboratories) with sera from all the leishmaniasis and control patients with the purpose of ruling out any double infection. We found that all patients with leishmaniasis and all the sera from control patients were negative. The apparent difference with respect to the specific reactivity of low-molecular-mass bands for T. cruzi reported by Chiller et al. (8) and the absence of anti-T. cruzi antibodies in sera from patients with leishmaniasis and controls for us could be due to differences in the Leishmania isolate, the type of antigen used, or the detection method used. However, like those investigators, we could not detect a polypeptide common to 100% of sera from patients with active infection. The most commonly recognized band was the 120-kDa band (76.7%).
To our knowledge, this is the first report of the bands revealed pre-and posttreatment for sera from patients with cutaneous leishmaniasis. Most published articles report on studies of patients with visceral leishmaniasis. However, in countries such as Colombia, where cutaneous leishmaniasis is so frequent and the risk of mucosal metastasis is so evident, it is important to develop new diagnostic tools for these patients. Our data suggest that Western blotting could be used when IIF is negative but the clinical feature of the disease is compatible with leishmaniasis because of the higher sensitivity of Western blotting. Besides, we propose that the band of 120 kDa could be helpful for the diagnosis of American cutaneous leishmaniasis.
Further work is needed to define the possible value of the 78-kDa band as a prognostic indicator.
